

**ALERT**



## NicOx to present at the Cowen and Company 30<sup>th</sup> Annual Health Care Conference on March 10

---

March 8, 2010. Sophia Antipolis, France. [www.nicox.com](http://www.nicox.com)

Michele Garufi, Chairman and CEO of NicOx (NYSE Euronext Paris: COX), will present an overview on the key achievements and strategy of the Company and the recent worldwide licensing agreement signed with Bausch + Lomb for NCX 116 at the Cowen and Company 30<sup>th</sup> Annual Health Care Conference in Boston on March 10, 2010 at 10:15 US Eastern Time (16:15 Central European Time – 15:15 UK Time).

To access the live audio broadcasts of the presentation or its subsequent archived recording please logon to <http://www.nicox.com>. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

---

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NME) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx's lead investigational compound is naproxcinod, an NME and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate developed for the relief of the signs and symptoms of osteoarthritis (OA), which is currently under review by regulatory authorities, following the submission and filing of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The FDA has set an action date of July 24, 2010, under the Prescription Drug User Fee Act (PDUFA).

In addition to naproxcinod, NicOx's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of hypertension, cardiometabolic diseases, widespread eye diseases and dermatological disease.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).



---

**CONTACTS:** <http://www.nicox.com>

**NicOx:** Karl Hanks • Director of Investor Relations and Corporate Communications  
Tel +33 (0)4 97 24 53 42 • [hanks@nicox.com](mailto:hanks@nicox.com)

**Media in the United States** – FD: Robert Stanislaro • Tel +1 212 850 5657 • [robert.stanislaro@fd.com](mailto:robert.stanislaro@fd.com)  
Irma Gomez-Dib • Tel +1 212 850 5761 • [irma.gomez-dib@fd.com](mailto:irma.gomez-dib@fd.com)

**Media in Europe** - Citigate Dewe Rogerson: David Dible • Tel +44 (0)207 282 2949 • [david.dible@citigatedr.co.uk](mailto:david.dible@citigatedr.co.uk)  
Nina Enegren • Tel: +44 (0)207 282 1050 • [nina.enegren@citigatedr.co.uk](mailto:nina.enegren@citigatedr.co.uk)